Capsid Thermal Stability

Executive Summary

Capsid Thermal Stability is the measure of an Adeno-Associated Virus (AAV) capsid's structural integrity and its resistance to unfolding or dissociation when subjected to increasing temperature. A higher melting temperature ( $T_{m}$ ) generally indicates a more stable capsid. This is a Critical Quality Attribute (CQA) because a physically stable capsid is essential for protecting the therapeutic DNA genome during manufacturing, shipping, and storage. Loss of thermal stability is directly linked to capsid disassembly and protein aggregation, which can lead to a loss of product potency and potentially increase immunogenicity.

Category: General Properties / Physicochemical Properties

Typical Reporting/Limits:

Reportable Value: One or more melting transitions (Tm1, Tm2) and/or aggregation onset temperature (Tonset); for DSC, report ΔH (enthalpy) when relevant.
Common Units: Degrees Celsius (°C).
Typical Acceptance Criteria: Product-specific; typically defined as ‘within validated control limits vs. reference/clinical material’ or as a permitted shift (e.g., |ΔTm| ≤ X °C) under fixed method conditions (buffer, pH, protein concentration, ramp rate).

Analytical Procedures

Context in Practice: Example Specifications

From Specification: Typical AAV Drug Product Specifications

Rationale: To confirm the capsid is properly folded and physically stable, ensuring it can protect the genome. It is a key indicator of manufacturing consistency.
Acceptance Criteria: Tm (and/or unfolding profile) comparable to reference within preset criteria.
Orthogonal Method(s): Differential Scanning Calorimetry (DSC)

Key Analytical Challenges

Assay Interference: Sample components (e.g., certain excipients or process residuals) that are themselves fluorescent can interfere with the assay and complicate data interpretation.
Dye Interaction: It is critical to ensure that the fluorescent dye used in the assay (e.g., SYPRO Orange) reports on the unfolding of the capsid and does not, by its own binding, significantly alter the stability of the particle.
Heating Rate Control: The observed $T_{m}$ can be dependent on the rate at which the temperature is increased (the ramp rate). This parameter must be precisely controlled for consistent and reproducible results.
Multiple transitions: AAV can exhibit Tm1/Tm2 (distinct structural events/uncoating); define which you report.
Genome content effect: Full vs empty capsids often show different Tm/Tagg; specify which species the method targets.
Matrix & excipient effects: Surfactants (e.g., polysorbates), sugars, salts, buffer pH/ionic strength shift signals; validate matrix suitability.
Protein concentration dependence: Tm/Tagg can be concentration-dependent; control/report concentration.
Instrument/method parameters: Ramp rate/equilibration, dye ratio (for DSF), baseline subtraction (for DSC), and temperature calibration must be controlled.

Phase-Appropriate CMC & Regulatory Expectations

Early Phase (Phase 1-2): Thermal stability is a key characterization tool used extensively in formulation development to screen buffers and excipients to find the most stabilizing conditions for the AAV product.
Late Phase & Commercial (Phase 3/BLA): Validated for its intended role (e.g., stability program trending and/or characterization). Inclusion as a release specification is product- and strategy-dependent and not universally required.

Risk Assessment

Product Risk (Efficacy & Potency): A product with low thermal stability is at a higher risk of the capsid dissociating or aggregating. This can lead to premature release and degradation of the DNA genome, resulting in a direct loss of potency.
Product Risk (Purity): Thermal unfolding is a primary pathway to protein aggregation. A loss of stability leads to the formation of product-related impurities (aggregates), impacting the product's purity profile.

Relationship to Other Attributes

Purity & Impurities: Directly linked. A decrease in thermal stability is often a leading indicator of future protein aggregation.
Potency/Biological Activity: A stable, intact capsid is a prerequisite for the vector to successfully transduce target cells. A loss of stability leads to a loss of potency.
Stability: This attribute is a direct, quantitative measure of the physical stability of the drug product.

Industry Commentary & Standards

Measuring capsid thermal stability is a standard part of AAV product characterization and formulation development across the industry. While the absolute $T_{m}$ value can vary significantly between different AAV serotypes and formulations, the expectation is that a given manufacturing process will produce a product with a consistent thermal profile.

Key Guideline Commentary

ICH Q6B: This guidance establishes the expectation that the physicochemical properties of biologics be characterized. Thermal stability is a key property that defines the product's structural integrity.
ICH Q5C: This guidance on the stability testing of biotechnological/biological products establishes the expectation that the stability of a product will be monitored over its shelf-life using appropriate analytical methods. DSF is a key stability-indicating method.